← All trials
NCT04743661
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Jul 30, 2027
- Completion date
- Jul 30, 2030
- First posted
- Feb 8, 2021
- Last posted
- Sep 29, 2021
- Enrollment
- 62
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pediatric Brain Tumor ConsortiumLead sponsor
- National Cancer Institute (NCI)Collaborator
- Y-Mabs, IncCollaborator
- Memorial Sloan-Kettering Cancer CenterCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.